Korea’s Orum stays local with $30M round to build out cell-penetrating platform

To expand its cell-penetrating antibody platform and build out its R&D labs in Boston and South Korea, Orum raised $30 million in a series B round from new investors IMM Investment, Smilegate Investment, KTB Network and Stassets Investment. Existing investors InterVest and KB Investment/Solidus Investment also participated.

As with its $8 million series A round in 2017, Orum Therapeutics Inc. (Daejeon, South Korea) tapped only Korean investors for Wednesday's B round (see "Starting Local, Going Global")...